This study investigated the use of targeted drugs after OncoFOCUSTM+KIT screening in patients with malignant melanoma, non-small cell lung cancer and metastatic colorectal cancer, and then audited the results against the National Comprehensive Cancer Network (NCCN) guidelines. The gene discussed is KIT; the disease is melanoma.